INTERNATIONAL PATENT: REMEGEN CO., LTD., 荣昌生物制药（烟台）股份有限公司 FILES APPLICATION FOR "USE OF ANTI-CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATE FOR TREATING GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"

Posted On: 2026-03-16

GENEVA, March 16 -- REMEGEN CO., LTD. (No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade ZoneYantai, Shandong 264006), 荣昌生物制药（烟台）股份有限公司 (中国山东省烟台市中国（山东）自由贸易试验区烟台片区烟台开发区北京中路58号) filed a patent application (PCT/CN2025/119274) for "USE OF ANTI-CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATE FOR TREATING GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION A...

Click here to read full article from source

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

INTERNATIONAL PATENT: REMEGEN CO., LTD., 荣昌生物制药（烟台）股份有限公司 FILES APPLICATION FOR "USE OF ANTI-CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATE FOR TREATING GASTRIC CANCER AND/OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA"